» Articles » PMID: 12884199

Dual-echo, Chemical Shift Gradient-echo Magnetic Resonance Imaging to Quantify Hepatic Steatosis: Implications for Living Liver Donation

Overview
Journal Liver Transpl
Date 2003 Jul 29
PMID 12884199
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

In living liver donation, a fatty liver poses risks for both recipient and donor. Currently, liver biopsy is the standard for assessing the presence and extent of steatosis. The goals of this study were to correlate a steatosis index derived from magnetic resonance imaging (MRI) to the histologic grade on biopsy as well as to determine the topographic distribution of steatosis within the liver. We examined the ability of dual-echo, chemical shift gradient-echo MRI to predict the degree of steatosis on liver biopsy. A total of 22 subjects received both a liver biopsy and detailed MRI evaluation. These individuals included 15 potential living donors and 7 patients with nonalcoholic fatty liver disease. MRI steatosis index was then compared with histologic grade on liver biopsy. The topographic distribution of hepatic steatosis was determined from those subjects in whom MRI detected hepatic steatosis. The steatosis index had a positive correlation with grade of steatosis on liver biopsy (correlation coefficient, 0.84). There was no significant variation in the degree of steatosis among segments. A steatosis index of >0.2 had good positive and negative predictive value for the presence of significant steatosis (>15%) on biopsy. Our quantitative MRI protocol can predict the degree of hepatic steatosis when it is minimal to moderate, and may obviate the need for liver biopsy for the purpose of quantification of steatosis in living donors. Fat saturation added to the MRI protocol may further improve diagnostic accuracy. This technique may be applicable to the larger population with hepatic steatosis.

Citing Articles

Diffuse and focal liver fat: advanced imaging techniques and diagnostic insights.

Miranda J, Key Wakate Teruya A, Leao Filho H, Lahan-Martins D, Tamura Sttefano Guimaraes C, de Paula Reis Guimaraes V Abdom Radiol (NY). 2024; 49(12):4437-4462.

PMID: 38896247 DOI: 10.1007/s00261-024-04407-4.


Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis.

Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M World J Gastroenterol. 2022; 27(46):7866-7893.

PMID: 35046618 PMC: 8678821. DOI: 10.3748/wjg.v27.i46.7866.


Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.

Renzulli M, Brandi N, Argalia G, Brocchi S, Farolfi A, Fanti S Radiol Med. 2022; 127(2):129-144.

PMID: 35028886 DOI: 10.1007/s11547-022-01449-w.


Donor Surgical Morbidity in Pediatric Living-Donor Liver Transplant: A Portuguese Experience.

Dos Santos J, Martins R, Lopes M Pediatr Gastroenterol Hepatol Nutr. 2021; 24(6):528-534.

PMID: 34796097 PMC: 8593358. DOI: 10.5223/pghn.2021.24.6.528.


Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy.

Pandey P, Pandey A, Dillhoff M, Schmidt C, Kamel I, Pawlik T J Gastrointest Surg. 2017; 22(2):344-360.

PMID: 28924922 DOI: 10.1007/s11605-017-3562-3.